U.S. Launches Early Trial of Zika Vaccine
August 3, 2016
(UPI) – A potential vaccine for the Zika virus has entered early clinical trials to assess its safety in humans, U.S. health officials announced Wednesday. The DNA-based vaccine contains genetic pieces of the Zika virus. It is intended to promote an immune response that would protect against the mosquito-borne virus that can cause devastating birth defects, according to a statement from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).